Abstract
Objective: To evaluate the impact of the oxytocin receptor antagonist atosiban on implantation and pregnancy rates after first ICSI trial in good prognosis cases. Design: Randomised controlled trial. Materials and Methods: The study included 182 women, prepared for first trial of ICSI for male or tubal factor infertility, using long agonist protocol, were randomized to receive 7.5 mg atosiban or placebo IV 20 minutes before embryo transfer (ET). Results: Fifty-eight (63.7%) cases had ongoing pregnancy in the study group while 44 (48.4%) cases had ongoing pregnancy in control group and this was statistically significant (p = 0.037). Implantation rates were 45.20%, and 34.69%, respectively, which was also statistically significant (p = 0.045). All of the intermediate cycle parameters were also comparable. Conclusion: Atosiban in the given dose and regimen improved both implantation and on going pregnancy rates in good prognosis cases undergoing first ICSI trial and blastocyst stage embryo transfer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical and Experimental Obstetrics & Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
